Alopecia - Pipeline Insight, 2025
Description
DelveInsight’s, “Alopecia - Pipeline Insight, 2025” report provides comprehensive insights about 18+ companies and 20+ pipeline drugs in Alopecia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Alopecia: Overview
Alopecia is a condition that causes hair loss, either in localized patches or across the entire scalp and body. It can affect people of all ages and genders, with varying degrees of severity. The most common forms include alopecia areata, an autoimmune disorder that leads to patchy hair loss, and androgenetic alopecia, commonly known as male or female pattern baldness. Alopecia can be triggered by a range of factors, including genetics, hormonal changes, autoimmune diseases, stress, or certain medical treatments. The signs and symptoms of alopecia vary depending on the type and severity of hair loss. In alopecia areata, the most common symptom is patchy hair loss, where small, round, smooth bald spots develop on the scalp or other areas of the body. In androgenetic alopecia, hair thinning occurs gradually, often starting at the temples or crown for men, while women may experience diffuse thinning across the scalp. Some people may also notice increased hair shedding, often seen during brushing or washing. In rare cases, complete loss of scalp hair (alopecia totalis) or body hair (alopecia universalis) can occur.
The pathology of alopecia varies depending on its type, but it generally involves disruptions in the normal hair growth cycle. In alopecia areata, an autoimmune response leads to the body’s immune system mistakenly attacking hair follicles, causing them to shrink and stop producing hair. This results in patchy hair loss, and in severe cases, more widespread hair loss. In androgenetic alopecia, the primary cause is a genetic sensitivity to dihydrotestosterone (DHT), a hormone that causes hair follicles to gradually shrink, leading to thinner, shorter hairs and eventual baldness.
The diagnosis of alopecia typically involves a thorough medical history, physical examination, and, in some cases, additional tests to determine the underlying cause of hair loss. During the physical exam, a dermatologist inspects the pattern of hair loss, the condition of the scalp, and may perform a ""pull test"" to assess the extent of shedding. If autoimmune or genetic factors are suspected, blood tests may be conducted to check for conditions like thyroid dysfunction or hormonal imbalances. A scalp biopsy may also be performed to examine the hair follicles under a microscope, helping to distinguish between different types of alopecia. The treatment of alopecia depends on its type and severity. For alopecia areata, corticosteroid injections or topical treatments are often used to suppress the immune response and promote hair regrowth. Minoxidil (Rogaine) is a widely used over-the-counter medication that helps stimulate hair growth in androgenetic alopecia, while finasteride (Propecia), a prescription oral medication, works by reducing dihydrotestosterone (DHT) levels in men.
""Alopecia- Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Alopecia pipeline landscape is provided which includes the disease overview and Alopecia treatment guidelines. The assessment part of the report embraces, in depth Alopecia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Alopecia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Alopecia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Alopecia Emerging Drugs
Further product details are provided in the report……..
Alopecia: Therapeutic Assessment
This segment of the report provides insights about the different Alopecia drugs segregated based on following parameters that define the scope of the report, such as:
Alopecia: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Alopecia therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Alopecia drugs.
Alopecia Report Insights
Current Treatment Scenario and Emerging Therapies:
Geography Covered
- Global coverage
Alopecia: Overview
Alopecia is a condition that causes hair loss, either in localized patches or across the entire scalp and body. It can affect people of all ages and genders, with varying degrees of severity. The most common forms include alopecia areata, an autoimmune disorder that leads to patchy hair loss, and androgenetic alopecia, commonly known as male or female pattern baldness. Alopecia can be triggered by a range of factors, including genetics, hormonal changes, autoimmune diseases, stress, or certain medical treatments. The signs and symptoms of alopecia vary depending on the type and severity of hair loss. In alopecia areata, the most common symptom is patchy hair loss, where small, round, smooth bald spots develop on the scalp or other areas of the body. In androgenetic alopecia, hair thinning occurs gradually, often starting at the temples or crown for men, while women may experience diffuse thinning across the scalp. Some people may also notice increased hair shedding, often seen during brushing or washing. In rare cases, complete loss of scalp hair (alopecia totalis) or body hair (alopecia universalis) can occur.
The pathology of alopecia varies depending on its type, but it generally involves disruptions in the normal hair growth cycle. In alopecia areata, an autoimmune response leads to the body’s immune system mistakenly attacking hair follicles, causing them to shrink and stop producing hair. This results in patchy hair loss, and in severe cases, more widespread hair loss. In androgenetic alopecia, the primary cause is a genetic sensitivity to dihydrotestosterone (DHT), a hormone that causes hair follicles to gradually shrink, leading to thinner, shorter hairs and eventual baldness.
The diagnosis of alopecia typically involves a thorough medical history, physical examination, and, in some cases, additional tests to determine the underlying cause of hair loss. During the physical exam, a dermatologist inspects the pattern of hair loss, the condition of the scalp, and may perform a ""pull test"" to assess the extent of shedding. If autoimmune or genetic factors are suspected, blood tests may be conducted to check for conditions like thyroid dysfunction or hormonal imbalances. A scalp biopsy may also be performed to examine the hair follicles under a microscope, helping to distinguish between different types of alopecia. The treatment of alopecia depends on its type and severity. For alopecia areata, corticosteroid injections or topical treatments are often used to suppress the immune response and promote hair regrowth. Minoxidil (Rogaine) is a widely used over-the-counter medication that helps stimulate hair growth in androgenetic alopecia, while finasteride (Propecia), a prescription oral medication, works by reducing dihydrotestosterone (DHT) levels in men.
""Alopecia- Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Alopecia pipeline landscape is provided which includes the disease overview and Alopecia treatment guidelines. The assessment part of the report embraces, in depth Alopecia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Alopecia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Alopecia R&D. The therapies under development are focused on novel approaches to treat/improve Alopecia.
This segment of the Alopecia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Alopecia Emerging Drugs
- Clascoterone: Cosmo Pharmaceuticals
- ADX-914: Q32 Bio Inc.
- SCO 240: SCOHIA PHARMA
Further product details are provided in the report……..
Alopecia: Therapeutic Assessment
This segment of the report provides insights about the different Alopecia drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Alopecia
- There are approx. 18+ key companies which are developing the therapies for Alopecia. The companies which have their Alopecia drug candidates in the most advanced stage, i.e. Phase III include, Cosmo Pharmaceuticals.
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical
- Molecule Type
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
- Product Type
Alopecia: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Alopecia therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Alopecia drugs.
Alopecia Report Insights
- Alopecia Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Alopecia drugs?
- How many Alopecia drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Alopecia?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Alopecia therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Alopecia and their status?
- What are the key designations that have been granted to the emerging drugs?
- Cosmo Pharmaceuticals
- Suzhou Kintor Pharmaceuticals
- Q32 Bio Inc.
- SCOHIA PHARMA
- Arcutis Biotherapeutics
- Aranda Pharma
- JW Pharmaceutical
- Clascoterone
- KX0826
- ADX-914
- GT 20029
- SCO 240
- ARQ-255
- ADA 308
- JW 0061
Table of Contents
80 Pages
- Introduction
- Executive Summary
- Alopecia: Overview
- Introduction
- Causes
- Pathophysiology
- Signs and Symptoms
- Diagnosis
- Treatment
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Alopecia– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Comparative Analysis
- Clascoterone: Cosmo Pharmaceuticals
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- ADX-914: Q32 Bio Inc.
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Comparative Analysis
- SCO 240: SCOHIA PHARMA
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Comparative Analysis
- Drug name: Company name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Alopecia Key Companies
- Alopecia Key Products
- Alopecia- Unmet Needs
- Alopecia- Market Drivers and Barriers
- Alopecia- Future Perspectives and Conclusion
- Alopecia Analyst Views
- Alopecia Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
